China Cord Blood Corporation (CO) Reaches New 12-Month High at $12.72
China Cord Blood Corporation (NYSE:CO) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $12.72 and last traded at $12.68, with a volume of 276,775 shares changing hands. The stock had previously closed at $12.26.
Separately, BidaskClub upgraded shares of China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 1st.
The stock has a market capitalization of $1.53 billion, a PE ratio of 53.38 and a beta of 0.94. The company’s 50-day moving average price is $10.71 and its 200-day moving average price is $7.96.
China Cord Blood Corporation (NYSE:CO) last announced its quarterly earnings data on Wednesday, June 21st. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.02. The firm had revenue of $29.35 million during the quarter. China Cord Blood Corporation had a net margin of 16.46% and a return on equity of 7.05%. Equities research analysts anticipate that China Cord Blood Corporation will post $0.15 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of CO. State Street Corp boosted its position in China Cord Blood Corporation by 1.7% in the second quarter. State Street Corp now owns 30,056 shares of the medical research company’s stock valued at $284,000 after buying an additional 506 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in China Cord Blood Corporation by 12.2% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 40,870 shares of the medical research company’s stock valued at $272,000 after buying an additional 4,442 shares during the last quarter. Financial Counselors Inc. boosted its position in China Cord Blood Corporation by 6.0% in the first quarter. Financial Counselors Inc. now owns 92,056 shares of the medical research company’s stock valued at $613,000 after buying an additional 5,226 shares during the last quarter. MML Investors Services LLC bought a new position in China Cord Blood Corporation during the second quarter valued at $104,000. Finally, Parametric Portfolio Associates LLC boosted its position in China Cord Blood Corporation by 82.5% in the second quarter. Parametric Portfolio Associates LLC now owns 34,542 shares of the medical research company’s stock valued at $327,000 after buying an additional 15,620 shares during the last quarter. 18.55% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.watchlistnews.com/china-cord-blood-corporation-co-reaches-new-12-month-high-at-12-72/1491576.html.
China Cord Blood Corporation Company Profile
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.